SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Sponsor: Stemline Therapeutics, Inc.
A PHASE1/PHASE2 clinical study on Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by Stemline Therapeutics, Inc. and has accumulated 13 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2023 — May 2024 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2022 — Dec 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
▶ Show 8 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Completed PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — May 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stemline Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .